The study will compare the prodisc C Vivo and prodisc C SK cervical discs with the Mobi-C, which received FDA approval in 2013.
The two-to-one randomized trial is enrolling patients with neck and arm pain who have not had a previous spine surgery.
The Mobi-C device will be used as a control to determine the safety and efficacy of the trial discs to treat cervical disc disease in patients unresponsive to nonoperative treatment at two levels.
More articles on devices:
Stryker ranks No. 8 in Fortune’s 100 best workplaces
Wuhan neurosurgeon, hospital director dies from coronavirus, death toll rises to 1,800+
Medtronic reports spine revenue up 3%, hurt by low BMP sales: 7 things to know
